- Lexaria, a global innovator in drug delivery platforms, recently announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study
- The study, a randomized, crossover investigation, will evaluate a dual-action glucagon-like peptide 1 (“GLP-1”) + glucose-dependent insulintropic peptide (“GIP”)
- It will measure absorption, tolerability, pharmacokinetics, and blood sugar levels
- Lexaria is counting on its patented DehydraTECH technology for significant growth in the 2024 calendar year, and the study reflects this commitment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study. This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The manufacturing of test articles for the study is expected to be completed soon, and the approval of an Independent Review Board (“IRB”) will be required before the study commences (https://ibn.fm/OrA8d).
This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (“GIP”), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, tirzepatide derived from Zepbound(R) and processed by Lexaria’s patented DehydraTECH technology. The objective would be to evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much.
This will mark Lexaria’s first-ever work with the tirzepatide molecule while also presenting an opportunity for alternative drug delivery, particularly given that tirzepatide is currently only available in injected form.
“Many GLP-1 drugs have produced unpleasant side effects, especially when dosed through oral tablets,” noted Chris Bunka, Lexaria’s CEO. “Lexaria’s latest study in an oral capsule hopes to evidence improved tolerability while also producing measurable quantities of drug in blood. This will be Lexaria’s first-ever work with the tirzepatide molecule and, as such, any noteworthy delivery of tirzepatide through oral delivery could be a significant finding,” he added.
Lexaria is counting on its DehydraTECH technology for significant growth in the 2024 calendar year. This study reflects this commitment and affirms the leadership’s confidence in the technology. It further looks to build on the technology’s success, as demonstrated in various studies since 2016, having shown its ability to increase bio-absorption compared to standard industry formulations. Lexaria’s management is optimistic that 2024 will be the company’s best year yet, and its tirzepatide study will be a testament to that.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
